About Stage Three COPD

Chronic obstructive pulmonary disease  (COPD) is a progressive disease that typically increases in severity over time. Stage Three COPD is a later stage in the disease’s progression. This stage is also called severe COPD.

Stage Three COPD Lung Capacities

A major sign that a person has COPD is the capacity of his or her lungs is decreased. Due to constant inflammation of the airways, COPD patients struggle to breathe properly. They have difficulty blowing out air with any force, and the overall volume of air they can hold in their lungs is diminished. When measuring lung capacity, a common measurement  is a combination of the forced expiratory volume (FEV1) and forced vital capacity (FVC) tests called the FEV1/FVC ratio.  A healthy person has a FEV1/FVC ratio of or around 80 percent. Thus the lower the FEV1/FVC ratio the more significant the disease.

COPD Stage Three is categorized by a FEV1 test score that is greater than 30 percent but less than 50 percent and a FEV1/FVC ratio of less than 70 percent.

Stage Three COPD Symptoms: 

  • Chronic coughing
  • Sputum: coughing up mucus
  • Dyspnea: breathing discomfort
  • Shortness of breath
  • Chest tightness
  • Unintended weight loss
  • Frequent respiratory infections

Stage Three COPD Treatment

There is no cure for COPD Stage three, but the following treatments can help with managing the disease:

  • Short-acting bronchodilator
  • Long-acting bronchodilator
  • Glucocorticosteroids
  • Smoking cessation  and monitoring environment to reduce airborne particles
  • Pulmonary rehabilitation class

If you would like to find out more about our available treatment options for COPD, please contact one of our patient care coordinators today at (800) 729-3065 to schedule a free consultation.

* All treatments performed at Lung Institute utilize autologous stem cells, meaning those derived from a patient's own body. No fetal or embryonic stem cells are utilized in Lung Institute's procedures. Lung Institute aims to improve patients' quality of life and help them breathe easier through the use of autologous stem cell therapy. To learn more about how stem cells work for lung disease, click here.

All claims made regarding the efficacy of Lung Institute's treatments as they pertain to pulmonary conditions are based solely on anecdotal support collected by Lung Institute. Individual conditions, treatment and outcomes may vary and are not necessarily indicative of future results. Testimonial participation is voluntary. Lung Institute does not pay for or script patient testimonials.

Under current FDA guidelines and regulations 1271.10 and 1271.15, the Lung Institute complies with all necessary requirements for operation. Any individual who accesses Lung Institute's website for information is encouraged to speak with his or her primary physician for treatment suggestions and conclusive evidence. All information on this site should be used for educational and informational use only.